Please login to the form below

Not currently logged in
Email:
Password:

FDA questions wider approval of Cymbalta

FDA scientists have noted that some of the statistical methodologies used to support data for the approval of Eli Lilly's Cymbalta appear 'problematic'

Eli Lilly has submitted data to the FDA ahead of an advisory panel meeting to support approval of its antidepressant Cymbalta (duloxetine) for chronic pain, but scientists have questioned some of the statistical methodologies used to study the drug and liver side-effects.

The advisory panel meeting was originally scheduled for January 2010, but it was delayed so the FDA could review additional information it said was "relevant to the benefit risk balance for the proposed new indication." The application is for a range of pain ailments, including lower back pain.

Cymbalta is currently approved in the US for depression, diabetic nerve pain and fibromyalgia. But FDA reviewers appeared cautious about expanding the use of the drug already used by nearly 15m patients.

The drugmaker has been trying to gain approval for the new indication for more than two years. It withdrew its application in November 2008 after the FDA questioned the method and design of the trials. The application was resubmitted last year.

Three studies showed Cymbalta lowered patient-reported pain score significantly more than a placebo after three months, but reviewers noted that positive feedback from patients who later dropped out of one of the studies, possibly due to side-effects, was included.

According to reviewers, this practice could "potentially assign good pain scores to subjects who could not tolerate the drug."

18th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...